The White Elephant in the Room–San Rocco Therapeutics’ $800K Gene Therapy Challenges Billion-Dollar Biotech Orthodoxy

In the trillion-dollar scramble to monetize gene therapy, two biotech titans—Bluebird Bio and CRISPR Therapeutics—dominated headlines, drew billions in speculative capital, and set eye-watering price tags: $3.1 million for Zynteglo, Bluebird’s gene replacement therapy for transfusion-dependent β-thalassemia (TDT), and $2.2 million for CRISPR’s gene editing option, Casgevy, for sickle cell disease (SCD). But while Wall Street buzzed, most patients remained priced out—and the promise of a cure remained aspirational.

Today, both companies are cautionary tales. Bluebird Bio, once valued at $12 billion, was quietly acquired this year for just $50 million—a fires sale.

CRISPR Therapeutics, which reached a $19 billion market cap at the height of the 2021 gene-editing boom, now trades at $3.7 billion. Their commercial gene therapies, despite FDA approval and early fanfare, reached only a sliver of eligible patients.

But there is another horse in this race—counted out by most media, biotech analysts, and investors.

View the rest of the article here

View the PDF